Ansun Biopharma

8 articles with Ansun Biopharma

• 

  Top 20 Life Science Startups to Watch in 2019

  1/7/2019

  BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

• Ansun Biopharma To Present at Biotech Showcase™ 2019 In San Francisco

  1/7/2019

  Ansun Biopharma, Inc., today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.

• Ansun Biopharma Announces Key Appointments to its Executive Management Team

  10/8/2018

  Ansun Biopharma is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral infections,

• Ansun BioPharma secures $85 million in Series A Financing

  5/14/2018

  Ansun is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections.

• 

  Ansun BioPharma Closes $85 Million Series A Financing

  5/14/2018

  Ansun Biopharma closed on a Series A financing round worth $85 million. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181.

• San Diego Ansun BioPharma's Drug Bestowed With Breakthrough Tag

  10/10/2017

• Ansun BioPharma Announces Two Publications Showing Inhibitory Effects Of DAS181 On Respiratory Syncytial Virus (RSV) And Human Metapneumovirus (hMPV)

  9/27/2016

• Ansun BioPharma Named Buzz Of BIO Winner For The 2016 BIO International Convention

  5/9/2016